Scilex Holding Company Unrealized Gain (Loss) on Investments
Scilex Holding Company (SCLX) reported Unrealized Gain (Loss) on Investments of -$82.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-14
- Scilex Holding Company unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$50.74M.
- Scilex Holding Company unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$31.71M.
- Scilex Holding Company unrealized gain (loss) on investments for the quarter ending 2025-12-31 was -$5.59M.
- Scilex Holding Company unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $8.28M.
- Scilex Holding Company unrealized gain (loss) on investments for fiscal 2025 was $2.69M.
- Scilex Holding Company unrealized gain (loss) on investments for fiscal 2024 was $0.00.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$50.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$82.45M 10-Q · filed 2026-08-14 | -$88.04M derived: sum of 3 quarters · filed 2026-08-14 | -$79.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$31.71M 10-Q · filed 2026-05-20 | -$37.30M derived: sum of 2 quarters · filed 2026-05-20 | -$29.02M derived: sum of 3 quarters · filed 2026-05-20 | -$29.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$5.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $2.69M derived: sum of 2 quarters · filed 2026-04-10 | $2.69M derived: sum of 3 quarters · filed 2026-08-14 | $2.69M 10-K · filed 2026-04-10 |
| 2025-09-30 | $8.28M 10-Q · filed 2025-11-14 | $8.28M derived: sum of 2 quarters · filed 2026-08-14 | $8.28M 10-Q · filed 2025-11-14 | $8.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-05-20 | $0.00 derived: sum of 3 quarters · filed 2026-05-20 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $0.00 derived: sum of 2 quarters · filed 2026-04-10 | $0.00 10-K · filed 2026-04-10 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |